Pr. Tim Hughes             Chronic Myeloid Leukemia           CML

''Professor Tim Hughes was promoted to Clinical Professor, University of Adelaide and was also awarded the 2006 Eric Susman Prize from the Royal Australasian College of Physicians for his original and groundbreaking research in chronic myeloid leukaemia (CML).  His contributions include defining the importance of molecular monitoring in CML patients receiving kinase inhibitor therapy, showing that the mutation profile helps clinicians to choose the best kinase inhibitor to use and using pre-therapy kinase sensitivity to tailor drug dose for each patients.  His work also led to a publication in the journal Nature describing the in-vivo kinetics of a human cancer.''
Extract of http://www.rah.sa.gov.au/cancer/haematology5.php
"Prof Timothy Hughes is the Beat Cancer Professor at the University of Adelaide and Head of the Cancer Theme at the South Australian Health and Medical Research Institute (SAHMRI). He currently holds a Practitioner Fellowship from the NHMRC. He is also a Consultant Haematologist in the Division of Haematology at SA Pathology. He is a Fellow of the Australian Academy of Health and Medical Sciences. He has been Principal Investigator for many of the CML trials conducted by the ALLG and been on the management committee for many of the key global CML trials using kinase inhibitors – IRIS, TOPS, ENESTnd, ENESTcmr, ENESTstop, DASISION, PACE, and EPIC.
He has published over 250 articles with over 20,000 citations. In 2009 he co-founded the International CML Foundation (iCMLf) with John Goldman and Jorge Cortes and was appointed Chair in 2014. He was awarded the Eric Susman Prize in 2006 for the most outstanding contribution to the knowledge of any branch of internal medicine by a Fellow of the Royal Australasian College of Physicians and was awarded the SA Science Excellence Award in the area of Excellence in Research in 2007. In 2011 his NHMRC Project grant was selected as one of best NHMRC Best Ten Research Projects nationally. He was a Director of HSANZ from 1997-2003, and served as President from 2001 to 2003, and the Australasian Leukaemia and Lymphoma Group (ALLG), for which he served as Vice Chairman from 2000 to 2005."
Extract of http://www.haa2015.com/program/speakers/prof-tim-hughes.html 

Other reference about Prof Timothy Hughes
VIDEOS

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML
December 2022, OncologyTube.com

World CML Day webinar with Professor Tim Hughes
September 22, 2020, Leukaemia Foundation - Blood Cancer Information

ENESTnd 5-year follow-up in patients with chronic myeloid leukemia in chronic phase from EHA 2014
June 23, 2014,  prIME Oncology

EHA19 CML Colloquium: Welcome note (Tim Hughes)                                          
June 19, 2014, iCMLf

Dr. Timothy Hughes Compares Imatinib to Nilotinib in Chronic Myeloid Leukemia
January 4, 2013, OncLiveTV

Second generation TKIs in chronic myeloid leukaemia
June 11,  2011,  ecancertv

Pr. Timothy Hughes at BTG2011                                                                                        
July 30, 2011, TheMedalGroup

ENESTnd trial comparing nilotinib and imatinib as first line CML therapy
February 18, 2011,  ecancertv

Practical recommendations for the management of CML patients: Interview with Prof. Timothy Hughes                                                                                                                          
December 2010,  iCMLf

Optimising Response and Managing Resistance to Treatment                              
December 2010,  iCMLf